Pages that link to "Q33393587"
Jump to navigation
Jump to search
The following pages link to Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis (Q33393587):
Displaying 50 items.
- JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms (Q21285040) (← links)
- Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis (Q24186554) (← links)
- Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes (Q26752940) (← links)
- Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest (Q26777398) (← links)
- Targeting JAK2 in the therapy of myeloproliferative neoplasms (Q26860796) (← links)
- Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors (Q26863610) (← links)
- Jakpot! New small molecules in autoimmune and inflammatory diseases (Q27001957) (← links)
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies (Q27002547) (← links)
- JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg? (Q27012572) (← links)
- The evolving treatment paradigm in myelofibrosis (Q27021968) (← links)
- Janus kinase inhibitors: jackpot or potluck? (Q27027230) (← links)
- Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms (Q27644628) (← links)
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors (Q27681896) (← links)
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology (Q27681935) (← links)
- Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes (Q28072745) (← links)
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms (Q28271752) (← links)
- Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells (Q28481327) (← links)
- Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients (Q28533511) (← links)
- MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. (Q30412320) (← links)
- SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data (Q30585642) (← links)
- Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. (Q31130829) (← links)
- EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. (Q33397674) (← links)
- Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis (Q33397838) (← links)
- Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib (Q33402522) (← links)
- Emerging drugs for myelofibrosis (Q33404574) (← links)
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis (Q33406238) (← links)
- Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis (Q33407924) (← links)
- Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells (Q33576089) (← links)
- AKT is a therapeutic target in myeloproliferative neoplasms (Q33623277) (← links)
- Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells (Q33894805) (← links)
- Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms (Q33982315) (← links)
- Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors (Q33982322) (← links)
- Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms (Q34021753) (← links)
- Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk‐stratification, and management (Q34166859) (← links)
- A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden (Q34189794) (← links)
- Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms (Q34302770) (← links)
- Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells (Q34344849) (← links)
- The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders (Q34349150) (← links)
- JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. (Q34471806) (← links)
- Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer (Q34552079) (← links)
- t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. (Q34570939) (← links)
- mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms (Q34575726) (← links)
- Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies (Q34629928) (← links)
- The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. (Q34640790) (← links)
- JAK/STAT signaling in hematological malignancies. (Q34641224) (← links)
- Investigational Janus kinase inhibitors. (Q34648724) (← links)
- Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib (Q34648812) (← links)
- A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling (Q34826329) (← links)
- Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele (Q35005652) (← links)
- Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia (Q35079398) (← links)